38 completed, 4 recruiting, 4 terminated, 4 unknown. 28 Phase 2, 23 Phase 3, 7 Phase 1, 4 Not applicable.
Follow Therapeutic Hydrocortisone: new trials by email Literature Review of Therapeutic Hydrocortisone trials Research Report on Therapeutic Hydrocortisone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-21 |
| Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome Biospecimen Collection, Cytarabine, Lumbar Puncture - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 26 | 2025-06-04 | 2026-06-26 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Fludarabine Phosphate - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2019-05-17 | 2025-04-13 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
| Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride - Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Phase 1 / Phase 2 | Unknown | Northwestern University | 38 | 2015-10-28 | 2022-02-21 |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 669 | 2014-12-17 | 2026-10-21 |
| Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma dexamethasone, vincristine sulfate, rituximab - Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma | Phase 2 | Completed | St. Jude Children's Research Hospital | 80 | 2013-04-15 | 2022-09-28 |
| Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab Doxycycline, Management of Therapy Complications, Placebo - Advanced Malignant Neoplasm, Dermatologic Complication | Phase 2 | Completed | Academic and Community Cancer Research United | 19 | 2012-08-31 | 2020-01-09 |
| Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 148 | 2009-03-01 | 2017-01-27 |
| Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Asparaginase, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia | Phase 3 | Completed | Children's Oncology Group | 218 | 2008-01-15 | 2024-07-15 |
| Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy dexamethasone, ketoconazole, therapeutic hydrocortisone - Prostate Cancer | Not applicable | Withdrawn | Roswell Park Cancer Institute | 2007-10-01 | 2013-02-01 | |
| Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma monoclonal antibody SGN-30, therapeutic hydrocortisone, ifosfamide - Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2007-01-01 | 2018-03-14 |
| Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer Calcitriol, Ketoconazole, Laboratory Biomarker Analysis - Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 51 | 2006-10-01 | 2017-06-14 |
| Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy ketoconazole, lenalidomide, therapeutic hydrocortisone - Prostate Cancer | Phase 2 | Completed | Case Comprehensive Cancer Center | 34 | 2006-09-01 | 2020-07-24 |
| Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma filgrastim, pegfilgrastim, rituximab - Lymphoma | Phase 2 | Completed | AIDS Malignancy Consortium | 34 | 2006-09-01 | 2018-06-06 |
| Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis anti-thymocyte globulin, busulfan, cyclophosphamide - Nonneoplastic Condition | Phase 3 | Unknown | Children's Cancer and Leukaemia Group | 288 | 2006-03-01 | 2013-09-17 |
Showing 20 of 56. Sign in to see all of them.
Leukemia (22) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (18) · Lymphoma (12) · Burkitt Lymphoma (9) · Prostatic Neoplasms (9) · Leukemia, Biphenotypic, Acute (7) · Lymphoma, Large B-Cell, Diffuse (5) · Leukemia, Myeloid, Acute (4) · Lymphoma, Non-Hodgkin (4) · Anemia, Refractory, with Excess of Blasts (3) · Lymphoma, Large-Cell, Anaplastic (3) · Lymphoma, Large-Cell, Immunoblastic (3) · Myelodysplastic Syndromes (3) · Anemia, Refractory (2) · Dendritic Cell Sarcoma, Interdigitating (2)
Children's Oncology Group (15) · National Cancer Institute (NCI) (9) · Alliance for Clinical Trials in Oncology (2) · Dana-Farber Cancer Institute (2) · Eastern Cooperative Oncology Group (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Roswell Park Cancer Institute (2) · AIDS Malignancy Consortium (1) · Academic and Community Cancer Research United (1) · Asan Medical Center (1) · Barbara Ann Karmanos Cancer Institute (1) · Case Comprehensive Cancer Center (1) · Children's Cancer and Leukaemia Group (1) · Dutch Childhood Oncology Group (1) · Fred Hutchinson Cancer Center (1)
United States (44) · Canada (15) · Australia (13) · Puerto Rico (8) · Switzerland (7) · France (6) · Belgium (5) · Germany (5) · Italy (5) · Netherlands (5) · New Zealand (5) · United Kingdom (5) · Austria (4) · Czechia (3) · Portugal (2)
Julio C. Barredo, MD (2) · A. O. Sartor, MD (1) · Alan S. Gamis, MD, MPH (1) · Aminah Jatoi (1) · Andrea Biondi (1) · Ariela Noy, MD (1) · Barbara L. Asselin, MD (1) · Barbara Pro, MD (1) · Bayard L. Powell, MD (1) · Ben K Watkins (1) · Beverly Lange (1) · Bhagirathbhai Dholaria (1) · Caroline A. Hastings, MD (1) · Catherine Patte, MD (1) · Charles Ryan, MD (1)
PMID 10499612, PMID 10820362, PMID 11426549, PMID 11600602, PMID 12239143, PMID 12560440, PMID 14747052, PMID 15020604, PMID 15042678, PMID 15353542, PMID 15368546, PMID 15637138, PMID 16556894, PMID 16609069, PMID 16809737, PMID 16888080, PMID 17039234, PMID 17132719, PMID 17136402, PMID 17138821, PMID 17404083, PMID 17407135, PMID 17611565, PMID 18089878, PMID 18371107, PMID 18493992, PMID 19020548, PMID 19029421, PMID 19064966, PMID 19304957, PMID 19638218, PMID 19648788, PMID 19884541, PMID 19895612, PMID 20007809, PMID 20056794, PMID 20124218, PMID 20378563, PMID 20407035, PMID 20413658, PMID 20679620, PMID 21280197, PMID 21444917, PMID 21496005, PMID 21849481, PMID 22210879, PMID 22215753, PMID 22392565, PMID 22488662, PMID 23321258
U10CA098543 (8), U10CA180886 (7), P30CA006516 (2), U10CA031946 (2), 2017 (1), P01CA068484 (1), P30CA015083 (1), P30CA016056 (1), P30CA016672 (1), P30CA022453 (1), P30CA060553 (1), U01CA070019 (1), U10CA030969 (1), U10CA032102 (1), UM1CA228823 (1)